Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMAcTION AAA817 versus standard of care in PSMA-positive metastatic castration-resistant prostate cancer after lutetium-177 PSMA therapy
jRCT2011250011Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Aug 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of actinium-225 PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by Novartis. Primary endpoints: Biochemical response rate and Radiographic progression-free survival. Started Aug 2026; status: recruiting.
02
Drugs
actinium-225 PSMA-617
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2011250011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250011.